The reason the FDA gave MACK Fast Track approval is because there are no current therapies for pancreatic cancer -- the drug meets an unmet medical need.

Baxter continues to enhance the growth prospects. Back-to-back approvals of three important treatment supports the bullish thesis.

December E-mini S&Ps (ESZ14 -1.19%) this morning are down -1.31% and European stocks are down -2.04% at a 13-1/4 month low as global stocks continue their downside correction.

A medical researcher turned biotech analyst highlights several companies with unique diagnostic and therapeutic technologies.

Baxter International, Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN [Albumin (Human)].

Baxter’s shares traded hands slightly $0.24 higher, hitting $76.58, or 0.31 percent after the company strike a deal to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. (NYSE:PFE) for a total cash amount of $635 million.